These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 3034169)
21. Tumor-targeted chemotherapy with SMANCS in lipiodol for renal cell carcinoma: longer survival with larger size tumors. Tsuchiya K; Uchida T; Kobayashi M; Maeda H; Konno T; Yamanaka H Urology; 2000 Apr; 55(4):495-500. PubMed ID: 10736490 [TBL] [Abstract][Full Text] [Related]
22. [Targeting cancer chemotherapy using lipiodol as a carrier of anticancer drugs for hepatocellular carcinoma]. Konno T; Maeda H Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 2-1):1043-50. PubMed ID: 2839112 [TBL] [Abstract][Full Text] [Related]
23. [Treatment of carcinomatous effusion with oily anticancer agents dissolved in lipiodol]. Kimura M; Konno T; Oda T; Yamashita R Gan To Kagaku Ryoho; 1990 Aug; 17(8 Pt 2):1579-82. PubMed ID: 2167635 [TBL] [Abstract][Full Text] [Related]
24. [Principle and therapeutic effect of lipophilic anticancer agent [SMANCS/lipiodol]: selective targeting with oily contrast medium]. Maeda H Gan To Kagaku Ryoho; 1989 Oct; 16(10):3323-31. PubMed ID: 2552930 [TBL] [Abstract][Full Text] [Related]
25. [Repeated arterial infusion of zinostatin stimalamer using port for advanced hepatocellular carcinoma]. Yoshikawa M; Ebara M; Fukuda H; Sugiura N; Saisho H Gan To Kagaku Ryoho; 1998 Feb; 25 Suppl 1():30-3. PubMed ID: 9512684 [TBL] [Abstract][Full Text] [Related]
26. [Subsegmental transcatheter hepatic arterial embolization under balloon occlusion of the corresponding hepatic vein with SMANCS]. Shibata H; Sogabe M; Tsutsui A; Yokoi T; Morimoto M; Fukuda T; Hayashi S; Muguruma N; Ohkita Y; Okahisa T; Okamura S; Ito S Gan To Kagaku Ryoho; 1998 Feb; 25 Suppl 1():133-40. PubMed ID: 9512701 [TBL] [Abstract][Full Text] [Related]
27. [SMANCS/lipiodol]. Maeda H Gan To Kagaku Ryoho; 1994 May; 21(6):907-13. PubMed ID: 8185354 [TBL] [Abstract][Full Text] [Related]
28. [Two cases of long-term survival with hepatocellular carcinoma following targeting therapy with SMANCS/lipiodol]. Inoue Y; Nakamura H Gan To Kagaku Ryoho; 1996 Jan; 23(1):99-101. PubMed ID: 8546478 [TBL] [Abstract][Full Text] [Related]
29. Image enhancement in computerized tomography for sensitive diagnosis of liver cancer and semiquantitation of tumor selective drug targeting with oily contrast medium. Maki S; Konno T; Maeda H Cancer; 1985 Aug; 56(4):751-7. PubMed ID: 3160453 [TBL] [Abstract][Full Text] [Related]
30. [Tumor selective drug delivery with lipid contrast medium (smancs/lipiodol): sustained antitumor effect, enhanced diagnostic value and quantification of dosage regimen]. Maeda H; Konno T; Iwai K; Maki S; Tashiro S Gan To Kagaku Ryoho; 1984 Apr; 11(4):814-26. PubMed ID: 6326681 [TBL] [Abstract][Full Text] [Related]
31. [Combination of transcatheter arterial infusion of SMANCS and embolization (SMANCS-TAE) for hepatocellular carcinoma]. Hirashima N Gan To Kagaku Ryoho; 1998 Feb; 25 Suppl 1():125-32. PubMed ID: 9512700 [TBL] [Abstract][Full Text] [Related]
32. [A case of hepatocellular carcinoma with tumor thrombus in the right atrium successfully treated by arterial administration of lipiodol-SMANCS]. Yamada K; Sato T; Yamada A; Tanaka S; Fujii S; Matuo R; Murata K; Manabe T; Oda J Gan To Kagaku Ryoho; 1999 Feb; 26(3):361-4. PubMed ID: 10065101 [TBL] [Abstract][Full Text] [Related]
33. [Our initial experience with SMANCS in TAE for liver cancer]. Fujita M; Inoue E; Kuroda C; Kasugai H; Sasaki Y; Nakano H; Imaoka S Gan To Kagaku Ryoho; 1998 Feb; 25 Suppl 1():105-8. PubMed ID: 9512697 [TBL] [Abstract][Full Text] [Related]
35. [Clinical experience of treatment of liver metastasis of renal cell carcinoma treated with SMANCS/Lipiodol therapy]. Umeda S; Ito K; Takahashi E; Kimura F; Sumitomo M; Kaji T; Hayakawa M; Asano T Hinyokika Kiyo; 2010 Oct; 56(10):543-9. PubMed ID: 21063157 [TBL] [Abstract][Full Text] [Related]
36. [Styrene maleic acid neocarzinostatin-transcatheter embolization for hepatocellular carcinoma--third report]. Hasegawa I; Hirashima N Gan To Kagaku Ryoho; 2002 Feb; 29(2):253-9. PubMed ID: 11865632 [TBL] [Abstract][Full Text] [Related]
37. [Antitumor activities of oily suspended YM881 (SMANCS) against VX2 carcinoma]. Kimura M; Konno T; Ohtsuka N; Mizumachi R; Oda T Gan To Kagaku Ryoho; 1989 Jun; 16(6):2183-8. PubMed ID: 2544148 [TBL] [Abstract][Full Text] [Related]
38. Tumor-targeted chemotherapy with lipid contrast medium and macromolecular anticancer drug (SMANCS) for renal cell carcinoma. Kobayashi M; Imai K; Sugihara S; Maeda H; Konno T; Yamanaka H Urology; 1991 Mar; 37(3):288-94. PubMed ID: 1848030 [TBL] [Abstract][Full Text] [Related]
39. [Tumor-targeted chemotherapy with lipid contrast medium and macro molecular anticancer agents theoretical considerations and clinical outcome]. Maeda H; Konno T Gan To Kagaku Ryoho; 1985 Mar; 12(3 Pt 2):773-82. PubMed ID: 2985005 [TBL] [Abstract][Full Text] [Related]
40. Clinicopathological study on combination therapy consisting of arterial infusion of lipiodol-dissolved SMANCS and transcatheter arterial embolization for hepatocellular carcinoma. Jinno K; Moriwaki S; Tanada M; Wada T; Mandai K; Okada Y Cancer Chemother Pharmacol; 1992; 31 Suppl():S7-12. PubMed ID: 1333912 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]